PPH - ETF AI Analysis
Top Page
VanEck Pharmaceutical ETF (PPH)
PPH, the VanEck Pharmaceutical ETF, earns a solid overall rating thanks to heavy exposure to strong global pharma leaders like Eli Lilly and Merck, which bring robust financial performance, promising drug pipelines, and supportive earnings outlooks. At the same time, holdings such as Teva and McKesson introduce some drag due to higher debt and profitability concerns, and the fund’s focus on the pharmaceutical sector means investors are exposed to industry-specific risks like regulatory changes and product setbacks.
PPH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.08B
- Region
- Global
- Expense Ratio
- 0.36%
- Beta
- 0.31
- Issuer
- VanEck
- Inception Date
- Dec 20, 2011
- Dividend Yield
- 1.79%
- Asset Class
- Equity
- Index Tracked
- MVIS US Listed Pharmaceutical 25
PPH Summary
VanEck Pharmaceutical ETF (PPH) is a fund that follows the MVIS US Listed Pharmaceutical 25 Index, focusing on major drug and healthcare companies. It owns well-known names like Eli Lilly and Merck, along with other global pharmaceutical firms that develop and sell medicines and treatments. Investors might consider PPH for long-term growth tied to new drugs, aging populations, and rising healthcare spending, while also getting diversification across many pharma stocks instead of picking just one company. A key risk is that it is heavily concentrated in the pharmaceutical sector, so its value can rise or fall sharply with changes in drug pricing, regulation, or healthcare news.
How much will it cost me?
PPH has an expense ratio of 0.36%, which means you’ll pay about $3.60 per year for every $1,000 invested. This cost is slightly higher than the cheapest broad-market index ETFs because PPH is a more specialized, sector-focused fund that requires more targeted management.
What would affect this ETF?
PPH could benefit from global aging populations, rising healthcare spending, and successful new drug launches by major holdings like Eli Lilly, Merck, and Novo Nordisk, especially if governments continue to support access to medicines. On the negative side, tighter drug price regulations, patent expirations, safety issues, or weaker economic conditions that pressure healthcare budgets could hurt profits for its large pharmaceutical companies and weigh on the ETF’s performance.
PPH Top 10 Holdings
PPH is essentially a bet on Big Pharma, with Eli Lilly sitting in the driver’s seat as a rising heavyweight that’s been powering recent gains. Merck and Pfizer are also pulling their weight, with steady-to-rising performance that helps keep the fund’s overall trajectory positive. On the flip side, Novo Nordisk and Haleon have been more mixed to lagging, acting like a bit of a brake on returns. With a tight focus on global pharmaceutical names and heavy concentration in a few U.S. giants, this ETF lives and dies by the fortunes of its largest drugmakers.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 22.11% | $230.30M | $1.33T | 67.86% | 72Outperform |
 MRK | Merck & Company | 12.40% | $129.12M | $368.89B | 73.30% | 80Outperform |
 NVO | Novo Nordisk | 5.43% | $56.54M | $176.13B | -20.06% | 73Outperform |
 PFE | Pfizer | 5.11% | $53.26M | $173.95B | 25.65% | 74Outperform |
 MCK | McKesson | 4.68% | $48.71M | $115.96B | 20.48% | 62Neutral |
 IL:TEVA | Teva | 4.60% | $47.95M | ILS 149.16B | 94.35% | 61Neutral |
 BMY | Bristol-Myers Squibb | 4.54% | $47.25M | $127.71B | 36.96% | 78Outperform |
 GSK | GlaxoSmithKline | 4.35% | $45.32M | $99.63B | 5.48% | 77Outperform |
 COR | Cencora | 4.36% | $45.36M | $63.13B | -3.04% | 70Neutral |
 HLN | Haleon PLC Sponsored ADR | 3.94% | $40.99M | $37.64B | -5.66% | 67Neutral |
PPH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PPH, the sentiment is Positive. The current price of 119.33 is above the 20-day moving average (MA) of 113.14, above the 50-day MA of 112.38, and above the 200-day MA of 107.03, indicating a bullish trend. The MACD of 1.63 indicates Negative momentum. The RSI at 68.33 is Neutral, neither overbought nor oversold. The STOCH value of 62.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PPH.
PPH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| PPH | $119.33 | $121.00(1.40% Upside) | $1.08B | 0.36% | 72Outperform |
 IXN | $134.69 | $185.90(38.02% Upside) | $9.37B | 0.37% | 65Neutral |
 GUNR | $53.53 | $60.58(13.16% Upside) | $7.02B | 0.46% | 60Neutral |
 SHLD | $63.78 | $75.63(18.58% Upside) | $6.72B | 0.50% | 65Neutral |
 COPX | $71.96 | $98.29(36.59% Upside) | $6.62B | 0.65% | 69Neutral |
 IXJ | $112.66 | $119.93(6.45% Upside) | $4.62B | 0.38% | 71Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PPH | VanEck Pharmaceutical ETF | 119.33 | 28.34 | 31.15% | |
| IXN | iShares Global Tech ETF | 134.69 | 24.51 | 22.25% | |
| GUNR | FlexShares Morningstar Global Upstream Natural Resources Index Fund | 53.53 | 11.27 | 26.67% | |
| SHLD | Global X Defense Tech ETF | 63.78 | -4.54 | -6.65% | |
| COPX | Global X Copper Miners ETF | 71.96 | 13.33 | 22.74% | |
| IXJ | iShares Global Healthcare ETF | 112.66 | 22.80 | 25.38% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.